RONC-06. VOLUMETRIC-MODULATED ARC WHOLE-BRAIN RADIOTHERAPY FOR THE PREVENTION OF PERMANENT ALOPECIA IN PEDIATRIC PATIENTS

• Published in: Neuro-oncology (Charlottesville, Va.) Va.), 2020-12, Vol.22 (Supplement_3), p.iii457-iii457
• Main Authors: Uto, Megumi, Umeda, Katsutsugu, Arakawa, Yoshiki, Takehana, Keiichi, Kamitori, Tatsuya, Iwai, Atsushi, Kato, Itaru, Saida, Satoshi, Hiramatsu, Hidefumi, Mineharu, Yohei, Tanji, Masahiro, Takita, Junko, Mizowaki, Takashi
• Format: Article
• Language: English
• Subjects: Radiation Oncology
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/noaa222.779

Abstract Permanent alopecia is a grave late complication of multi-drug chemotherapy (CTx) plus cranial irradiation, reducing both patient self-esteem and quality of life in pediatric patients. We started to use craniospinal irradiation (CSI) using the volumetric-modulated arc whole-brain radiotherapy (VMAT-WBRT) in order to prevent permanent alopecia. We treated 5 pediatric patients with CSI using VMAT-WBRT, and report the initial clinical outcome. Five consecutive patients (4–11 years old) who received CSI using VMAT-WBRT from June 2015 to November 2018 were included into this study. One patient with embryonic carcinoma received radiotherapy (RT) with concurrent CTx; four patients with medulloblastoma (two patients with standard risk, and two patients with high risk) received RT followed by CTx. The prescribed doses of CSI were 23.4–35.2 Gy in 13–22 fractions, respectively. Optimization for VMAT-WBRT was performed to reduce doses to the hair follicles with keeping the dose coverage to the planning target volume. Although all patients experienced temporary alopecia, their hair fully recovered over the whole scalp within 8 months after finishing RT. One patient had disease progression after 6 months after completing CTx; this patient who was diagnosed as Group 3 subtype had diffuse meningeal dissemination confirmed with contrast enhanced spinal MRI before RT. The other four patients had no evidence of recurrence. Although CSI with VMAT-WBRT might be one of considerable options, more cases are needed to verify the efficacy to prevent permanent alopecia for pediatric patients who receive multi-drug CTx and cranial irradiation.